Kronos Bio Q2 EPS $(0.52) Misses $(0.46) Estimate, Sales $1.86M Beat $1.67M Estimate
Portfolio Pulse from Benzinga Newsdesk
Kronos Bio (NASDAQ:KRON) reported Q2 losses of $(0.52) per share, missing the analyst consensus estimate of $(0.46) by 13.04 percent. However, the company's quarterly sales of $1.86 million beat the analyst consensus estimate of $1.67 million by 11.62 percent.
August 08, 2023 | 10:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Kronos Bio's Q2 earnings per share missed estimates, but sales beat expectations.
Kronos Bio's Q2 earnings per share missed estimates, which could negatively impact the stock. However, the company's sales beat expectations, which could offset the negative impact of the earnings miss.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100